Navigation Links
TPI Reports First Quarter Fiscal Year 2014 Financial Results
Date:11/15/2013

,31067,602Interest expense(102,901)(108,404)Total other expenses(80,591)(40,802)Income before provision for income taxes2,093,6002,104,001Provision for income taxes634,108583,048Net income1,459,4921,520,953Less: net loss attributable to noncontrolling interest(55,631)(20,664)Net income attributable to Tianyin Pharmaceutical Co., Inc.$1,515,123$1,541,617Basic earnings per share$0.05$0.05Diluted earnings per share$0.05$0.05Weighted average number of common shares outstanding:Basic29,382,79129,332,791Diluted29,382,79129,332,791 Tianyin Pharmaceutical Co., Inc.Consolidated Statements of Comprehensive Income(Unaudited)For the Three Months EndedSeptember 30,20132012Net income$1,459,492$1,520,953Other comprehensive income (loss)Foreign currency translation adjustment612,662(112,500)Total other comprehensive income (loss)612,662(112,500)Total Comprehensive income2,072,1541,408,453Less: Comprehensive income (loss) attributable to the noncontrolling interest(54,474)(21,024)Comprehensive income attributable to Tianyin Pharmaceutical Co., Inc.$2,126,628$1,429,477 Tianyin Pharmaceutical Co., Inc.Consolidated Statements of Cash Flows(Unaudited)For the Three Months EndedSeptember 30,20132012Cash flows from operating activities:Net Income$

1,459,492$

1,520,953Adjustments to reconcile net income to net cashprovided by (used in) operating activities:Depreciation and amortization647,294583,704  Share-based payments-13,095  Changes in current assets and current liabilities:Accounts receivable285,687993,591Inventory397,873(577,022)Advance payments-640,981Other current assets313,900(39,736)Accounts payable and accrued expenses41,043(96,477)Accounts payable – construction related(2,728,333)(328,853)Trade notes payable-(3,085,485)Advances from customer-1,139,256Income tax and other taxes payable(193,381)(240,212)Other current liabilities22,011(40,444)Net cash provided by operating activities245,586483,
'/>"/>

SOURCE Tianyin Pharmaceutical Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Nephros Reports Third Quarter 2013 Financial Results and Completes Bridge Financing
2. Vermillion Reports Third Quarter 2013 Results
3. Global Radiopharmaceutical Market 2012-2016 Reports
4. SPO Global Reports Results for Third Quarter 2013
5. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2014 Results; Teleconference and Webcast to be held on November 14, 2013
6. PTC Therapeutics Reports Third Quarter 2013 Financial and Corporate Results
7. EntreMed Reports Third Quarter 2013 Financial Results
8. Intercept Pharmaceuticals Reports Third Quarter 2013 Financial Results
9. Simcere Pharmaceutical Group Reports Preliminary Unaudited Third Quarter 2013 Results
10. Aratana Therapeutics Reports Third Quarter 2013 Financial Results
11. Regulus Reports Third Quarter 2013 Financial Results and Recent Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... -- According to market research report, ... & Laboratory), Industry (Food, Pharmaceutical, Biotechnology, Surgical Procedure, ... Geography - Global Trends & Forecast to 2019", ... market on the basis of various types, applications, ... market size of each of these segments in ...
(Date:9/19/2014)... , Sept. 19, 2014  Lpath, Inc. ... in bioactive lipid-targeted therapeutics, announced today that it ... registered shares of common stock and 3,605,042 unregistered ... purchase price for one registered share of common ... unregistered share of common stock will be $3.475.  ...
(Date:9/19/2014)... September 19, 2014 Aufgrund ... den äußerst erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, der jetzt auch ... PDF, verfügbar unter pharmaserialisation.com , zeigt die ... jeweils in Kraft treten. Für international ... länger um das "ob", sondern darum, "wann" sie ...
Breaking Medicine Technology:Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2
(Date:9/19/2014)... (PRWEB) September 19, 2014 Boston Scientific ... mesh lawsuit ( http://www.transvaginalmeshlawsuithelp.com/ ) that is scheduled ... month, Bernstein Liebhard LLP reports. According to ... Court, the company asserts that claims involving its Solyx ... Practice and Remedies Code, a section of which shields ...
(Date:9/19/2014)... brain structure could help predict how willing you are to ... Yale University found those with greater volume in a part ... more likely to engage in risky behavior than people with ... by the U.S. National Institute on Aging, involved two groups ... The researchers sought to determine how brain structure influences risk ...
(Date:9/19/2014)... News) -- Although there is mounting evidence that ... and older adults in the United States don,t ... new research. Less than one-quarter of adults ... the Department of Health and Human Services, the ... promoting health and fitness and staying independent, researchers ...
(Date:9/19/2014)... Alan Mozes HealthDay Reporter ... Cancer patients burdened by stress and family conflicts before ... their operation, a new study suggests. Investigators found ... have a nearly three times greater risk for complications ... of life. "We,ve long known that patient quality ...
(Date:9/19/2014)... 2014 Lipitor lawsuits ( http://www.thelipitorlawsuit.com/ ... to develop Type 2 diabetes continue to move forward ... District Court, District of South Carolina, Bernstein Liebhard LLP ... 12, 2014, discovery is underway and moving forward in ... Pfizer, Inc., the manufacturer of Lipitor, has produced millions ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 4Health News:Brain Structure Might Help Predict Risky Behavior 2Health News:Adults Over 45 Not Meeting U.S. Muscle Strengthening Guidelines, Study Says 2Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 2Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 3Health News:Lipitor Lawsuits Move Forward, as Discovery Proceeds in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuits Move Forward, as Discovery Proceeds in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 3
... ATLANTA, Feb. 3 Brent McKenzie, based ... Consulting, the nation,s fastest growing,pharmacy benefit firm, ... Mr. McKenzie offers his clients over ... Benefits and Pharmacy Benefit Management arena.,Brent has ...
... Cancer Care Access, Efficiency and Quality; Created Based ... 3 /PRNewswire-USNewswire/ -- The National Policy ... the nation,s largest cancer treatment and research networks ... Principles for Reforming Cancer Care, designed to guide ...
... of medical research, study finds , , TUESDAY, Feb. 3 ... white parents to distrust medical research, which may explain ... So conclude University of Pittsburgh researchers who surveyed 190 ... to a primary-care clinic. , The parents were asked ...
... 2009) Green tea products have become regarded as a ... its benefit against a variety of diseases, including cancer. ... tea may counteract the anticancer effects of one cancer ... contraindicated for patients taking this medicine to ensure its ...
... study suggests that Capn4, a protein involved in cell ... after liver transplantation. Capn4 could potentially be used as ... These findings are in the February issue of ... Sons on behalf of the American Association for the ...
... popular assumptions about the health benefits of green tea, ... found that the widely used supplement renders a cancer ... lymphoma completely ineffective in treating cancer. , The ... extract (GTE) called EGCG destroys any anticancer activity of ...
Cached Medicine News:Health News:Brent McKenzie Joins ARMSRx Pharmacy Benefit Consulting 2Health News:US Oncology Adopts Principles for Reforming Cancer Care 2Health News:US Oncology Adopts Principles for Reforming Cancer Care 3Health News:Parental Distrust May Explain Lack of Black Children in Clinical Trials 2Health News:Green tea may negate the effects of a common cancer therapy 2Health News:Green tea may negate the effects of a common cancer therapy 3Health News:Protein predicts liver cancer recurrence and after transplantation 2Health News:USC study finds that green tea blocks benefits of cancer drug 2
...
A modular concept consisting of two J-Arms, to be fixed at any position of the skull clamp, allowing to the surgeon an unobstructed access to the surgical field....
Spoon end periosteal, polished finish, designed for large mucoperiosteal flaps....
Iowa University periosteal elevator, blade width 11/16" (17 mm), length 7 1/4" (184 mm)....
Medicine Products: